Lyell Immunopharma (LYEL) Price/FCF Ratio: History & Chart

Lyell Immunopharma, Inc.(LYEL)

Biotechnology · South San Francisco, CA

$8.70-0.37 (-4.08%)

Delayed quote: Oct 6, 2026, 11:00 AM EDT

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

South San Francisco, CA

161 employees

www.lyell.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lynn Seely

View full financials

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Lyell Immunopharma, Inc. (LYEL)	$213.19M	N/A	N/A	N/A	N/A
Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›	$214.19M	N/A	N/A	N/A	N/A
Compugen Ltd. (CGEN)vs ›	$215.11M	N/A	N/A	N/A	N/A
Niagen Bioscience Inc (NAGE)vs ›	$214.64M	37.83	48.24	64.03	64.30
Alector, Inc. (ALEC)vs ›	$209.91M	N/A	3.22	3.23	4.48
Keros Therapeutics, Inc. (KROS)vs ›	$224.44M	N/A	9.31	9.38	9.38
Biodesix, Inc. (BDSX)vs ›	$228.42M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$198.76M	N/A	N/A	N/A	N/A
MacroGenics, Inc. (MGNX)vs ›	$232.32M	N/A	99.21	99.21	99.21
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$192.58M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/FCF RATIO

TTM

Lyell Immunopharma, Inc. (LYEL)

$213.19M

N/A

Anbio Biotechnology Class A Ordinary Shares (NNNN)vs ›

$214.19M

N/A

Compugen Ltd. (CGEN)vs ›

$215.11M